COP vs LCTX · P/E 19, rev $58.94B vs rev $9.5M
ConocoPhillips (COP) versus Lineage Cell Therapeutics Inc (LCTX) — a side-by-side from cached financials, not a winner call.
ConocoPhillips (COP) is a oil & gas e&p company listed on NYSE. It is led by Ryan Lance.
Lineage Cell Therapeutics Inc (LCTX) is a biotechnology company listed on US.
Latest reported COP revenue for 2025-12-31 was $58.94B. Net income was $7.99B. Revenue was up 7.7% from 2024-12-31 to 2025-12-31. COP currently screens at market cap $135.49B and trailing P/E 18.8.
Latest reported LCTX revenue for 2024-12-31 was $9.5M. Net income was -$18.6M. Revenue was up 354.9% from 2023-12-31 to 2024-12-31. LCTX currently screens at market cap $213.6M.
COP currently screens at market cap $135.49B and trailing P/E 18.8. LCTX currently screens at market cap $213.6M.
Not investment advice. Open the COP and LCTX stock pages for the full models.
Not investment advice.